Pharma and biotech companies must produce safe, efficacious medicines more efficiently than ever to optimize time-to-market and competitiveness. Both public and proprietary data hold valuable insights for impactful decision making. Data integration and common ontologies are needed if organizations are to tap the potential of this data by leveraging, machine learning (ML) and Artificial Intelligence (AI). In addition, companies need flexible workflows that support ad-hoc analytics, integrate internal and external data, and democratize the high-value models generated by their data science teams.
During this panel, case studies from Pfizer and Denovicon Therapeutics will be followed by a discussion, with Dassault Systemes, on possible strategies to make this transformation and accelerate Drug Discovery.